STOCK TITAN
  1. Home
  2. News
  3. DXCM

DexCom, Inc. - DXCM STOCK NEWS

Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.

DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.

DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.

Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.

The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.

News

Dexcom Announces Upcoming Conference Presentation

Rhea-AI Summary
DexCom, Inc. (DXCM) to Present at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day

Rhea-AI Summary
DexCom, Inc. (NASDAQ: DXCM) Unveils #SeeDiabetes Campaign and Portrait Gallery to Raise Awareness for Expanding Access to Diabetes Technology. The campaign features a first-of-its-kind global portrait gallery of people living with diabetes, including celebrities Nick Jonas, Patti LaBelle, and Jeremy Irvine. Dexcom's efforts have expanded CGM coverage by 6 million people globally, reinforcing their commitment to broadening access to critical diabetes technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
News

Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2

Rhea-AI Summary
DexCom, Inc. (NASDAQ: DXCM) announces new market research and NICE recommendations on the benefits of Hybrid Closed Loop Systems (HCL) for people with diabetes. The research indicates that 79% of people struggle to keep their glucose levels in range, and almost half don't understand the benefits of HCL. The NICE TA for HCL systems will impact over 150,000 people living with Type 1 diabetes in England.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
News

Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

Rhea-AI Summary
DexCom reports Q3 2023 financial results with revenue growth of 27% to $975.0 million. The company secures reimbursement for Dexcom ONE in France and receives regulatory clearance for Dexcom G7 in Canada. DexCom raises its full-year revenue and margin guidance and announces a $500 million share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
buyback earnings
-
News

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Rhea-AI Summary
Dexcom announces availability of Dexcom G7 Continuous Glucose Monitoring System for Canadians with diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
-
News

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

Rhea-AI Summary
DexCom announces new clinical study outcomes at the 59th Annual Meeting of the European Association for the Study of Diabetes, highlighting the benefits of CGM use and the expanding portfolio of automated insulin delivery offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
clinical trial
News

Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

Rhea-AI Summary
DexCom to release Q3 2023 financial results on October 26, 2023. Conference call to review performance at 4:30 p.m. ET. Webcast available on investor relations website. Dial-in details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
earnings
-
News

Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition

Rhea-AI Summary
Dexcom and RxFood partner to introduce an improved digital health solution for diabetes management in Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
AI
-
News

Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program

Rhea-AI Summary
Dexcom U launches second season with expanded roster of athletes with diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
News

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France

Rhea-AI Summary
DexCom announces availability of Dexcom ONE real-time CGM sensor in France, expanding access to half a million more people with diabetes. Dexcom ONE shown to improve time-in-range significantly more than Flash Glucose Monitoring. Dexcom real-time CGM clinically proven to lower HbA1C, reduce hyper- and hypoglycemia, and increase time in range.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none

FAQ

What is the current stock price of DexCom (DXCM)?

The current stock price of DexCom (DXCM) is $80.04 as of December 20, 2024.

What is the market cap of DexCom (DXCM)?

The market cap of DexCom (DXCM) is approximately 30.6B.

What does DexCom, Inc. specialize in?

DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetic patients.

When was DexCom, Inc. founded?

DexCom, Inc. was founded in 1999.

What are some of DexCom's key products?

Key products include the Dexcom G6 and Dexcom G7 CGM systems.

How do DexCom's CGM systems benefit diabetic patients?

DexCom's CGM systems provide real-time glucose readings, helping patients and clinicians better manage diabetes.

What recent achievements has DexCom made?

Recent achievements include international market expansion and continuous product enhancements.

How is DexCom integrating its CGM systems with other technologies?

DexCom is integrating its CGM systems with insulin pumps from Insulet and Tandem for automatic insulin delivery.

What is the significance of DexCom's strategic partnerships?

Strategic partnerships enhance DexCom's market presence and technological capabilities.

What is DexCom's approach to innovation?

DexCom is committed to innovation, focusing on research and development to advance diabetes management.

How does DexCom support the community?

DexCom empowers patients, caregivers, and clinicians by delivering effective diabetes management solutions.

What financial trends are seen in DexCom's performance?

DexCom has shown robust growth with increasing revenues and strong market performance.

Stock DXCM logo
DexCom, Inc.

Nasdaq:DXCM

DXCM Rankings

#391 Ranked by Market Cap
N/A Ranked by Dividends

DXCM Stock Data

30.65B
389.05M
0.32%
97.12%
2.33%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO